RORγt inhibitor 1 is primarily used in research and therapeutic applications targeting autoimmune diseases and inflammatory conditions. It works by modulating the RORγt receptor, which plays a critical role in the differentiation and function of Th17 cells, a subset of T cells involved in inflammation. By inhibiting RORγt, this compound helps reduce the production of pro-inflammatory cytokines like IL-17, which are implicated in diseases such as psoriasis, rheumatoid arthritis, and multiple sclerosis. Its application extends to preclinical studies aimed at understanding the mechanisms of immune regulation and developing novel treatments for chronic inflammatory disorders. Additionally, it holds potential in oncology research, as Th17 cells and their associated pathways are also linked to tumor progression and immune evasion.